ArticleDie Ophthalmologie2026
[Retinal artery occlusion in Germany: results from the oregis registry].
Article in Die Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe oregis registry is Germany's first nationwide platform for real-world ophthalmological data. Launched as a multicenter, hypothesis-free registry by the German Society of Ophthalmology (DOG), oregis continuously collects treatment data from outpatient practices and clinics. With currently more than 2.5 million patients, oregis offers an unprecedented database for ophthalmological health research. Despite its clinical relevance, epidemiological and real-world data on the treatment of retinal artery occlusion (RAO) remain limited and based on small cohorts. This leads to uncertainties regarding patient characteristics, risk profiles and treatment strategies. oregis offers a unique opportunity to review RAO case data in a large, unselected population. The aim of this study was therefore to provide a descriptive overview of RAO patients and to demonstrate the potential of oregis for ophthalmological care.
methodsA search was performed for patients diagnosed with RAO between 2010 and 2025. The data retrieved from participating centers were anonymized.
resultsIn this study 832 patients were identified of which two thirds were male and one third female. The mean age was 70 years. At initial presentation 33% of patients showed a decimal best-corrected visual acuity (BCVA) > 0.5, 30% exhibited BCVA levels of hand motion, light perception or worse. At follow-up the overall distribution of visual function remained largely unchanged.
conclusionThe results confirm previously described epidemiological patterns of RAO, while simultaneously identifying areas in which the quality of documentation requires improvement. Furthermore, this study also underscores the potential of oregis as it enables the generation of big data by compiling large patient cohorts and longitudinal long-term information.
Indexed as
Identifiers
42850291What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.